Biotin Interference in the Measurement of Thyroid Hormone
A 47-year-old man with multiple sclerosis (MS) presented for routine follow-up and underwent a battery of laboratory tests because of a change in his drug therapy for MS. He was found to have hyperthyroidism with positive thyroid-specific autoantibodies. This determination was made by an immunoassay based on streptavidin-biotin interaction. As the laboratory finding was not correlated with any clinical abnormality, no thyrostatic treatment was initiated. On further questioning, the patient stated that he was taking 300 mg of biotin daily to treat his MS. Another test with a non-biotinylated assay yielded normal findings.
It should be borne in mind that discrepancies between the clinical presentation and the laboratory findings of patients taking biotin may be due to biotin interference with the test. The test values that may be affected include endocrinological parameters, tumor markers, and myocardial lesion markers. There is some evidence for the efficacy of high-dose biotin intake against progressive MS; as clinical trials of this question are currently ongoing, it must be assumed that an increasing number of patients are high-dose biotin users. Biotin intake should be paused two to five days before streptavidin-biotin-based assays are used. Non-biotinylated assays are an alternative.
Dr. med. Viktoria F. Köhler, Klinikum der Universität München, Germany, Medizinische Klinik und Poliklinik IV, Viktoria.Koehler@med.uni-muenchen.de
Dr. med. Ulrike Mann, Prof. Dr. med. W. Alexander Mann, MVZ Endokrinologikum Frankfurt/Main, Germany
Conflict of interest statement: The authors state that they have no conflict of interest.
Translated from the original German by Ethan Taub, M.D.
Cite this as: Köhler VF, Mann U, Mann WA: Biotin interference in the measurement of thyroid hormone. Dtsch Arztebl Int 2018; 115: 500 DOI: 10.3238/arztebl.2018.0500
Reactions Weekly, 201910.1007/s40278-019-70898-0